{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T03:24:54Z","timestamp":1791602694208,"version":"4.3.4"},"reference-count":90,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000062","name":"National Institute of Diabetes and Digestive and Kidney Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000062","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["5T32DK060414-18"],"award-info":[{"award-number":["5T32DK060414-18"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","theclinics.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.cld.2024.06.007","type":"journal-article","created":{"date-parts":[[2024,7,23]],"date-time":"2024-07-23T11:37:53Z","timestamp":1721734673000},"page":"633-646","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Alcohol and Hepatocellular Carcinoma"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1980-1807","authenticated-orcid":false,"given":"Nghiem B.","family":"Ha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.cld.2024.06.007_bib1","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/j.cgh.2022.06.032","article-title":"Hepatocellular carcinoma incidence in alcohol-associated cirrhosis: systematic review and meta-analysis","volume":"21","author":"Huang","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2024.06.007_bib2","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1002\/hep.29887","article-title":"The high burden of alcoholic cirrhosis in privately insured persons in the United States","volume":"68","author":"Mellinger","year":"2018","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2024.06.007_bib3","doi-asserted-by":"crossref","first-page":"270","DOI":"10.14309\/ajg.0000000000002405","article-title":"The rising costs of alcohol-associated liver disease in the United States","volume":"119","author":"Julien","year":"2024","journal-title":"Am J Gastroenterol"},{"issue":"5 Suppl 1","key":"10.1016\/j.cld.2024.06.007_bib4","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1053\/j.gastro.2004.09.011","article-title":"Primary liver cancer: worldwide incidence and trends","volume":"127","author":"Bosch","year":"2004","journal-title":"Gastroenterology"},{"issue":"1","key":"10.1016\/j.cld.2024.06.007_bib5","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2018-000260","article-title":"Alcohol and hepatocellular carcinoma","volume":"6","author":"Matsushita","year":"2019","journal-title":"BMJ Open Gastroenterol"},{"issue":"10360","key":"10.1016\/j.cld.2024.06.007_bib6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","article-title":"Hepatocellular carcinoma","volume":"400","author":"Vogel","year":"2022","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.cld.2024.06.007_bib7","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.cgh.2021.01.005","article-title":"Risk of cancer in biopsy-proven alcohol-related liver disease: a population-based cohort study of 3410 persons","volume":"20","author":"Hagstrom","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2024.06.007_bib8","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.cgh.2006.05.013","article-title":"Risk factors for hepatocellular carcinoma in patients with alcoholic or viral C cirrhosis","volume":"4","author":"N'Kontchou","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"15","key":"10.1016\/j.cld.2024.06.007_bib9","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1200\/JCO.2015.64.7412","article-title":"Future of hepatocellular carcinoma incidence in the United States forecast through 2030","volume":"34","author":"Petrick","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.cld.2024.06.007_bib10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/j.cld.2012.08.004","article-title":"Histologic findings in alcoholic liver disease","volume":"16","author":"Crawford","year":"2012","journal-title":"Clin Liver Dis"},{"issue":"4","key":"10.1016\/j.cld.2024.06.007_bib11","first-page":"277","article-title":"Alcohol, oxidative stress, and free radical damage","volume":"27","author":"Wu","year":"2003","journal-title":"Alcohol Res Health"},{"issue":"10152","key":"10.1016\/j.cld.2024.06.007_bib12","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","article-title":"Alcohol use and burden for 195 countries and territories, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016","volume":"392","author":"GBDA","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2024.06.007_bib13","doi-asserted-by":"crossref","DOI":"10.1097\/HEP.0000000000000890","article-title":"Alcohol-associated liver cancer","author":"Fu","year":"2024","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.cld.2024.06.007_bib14","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1038\/nrc2191","article-title":"Molecular mechanisms of alcohol-mediated carcinogenesis","volume":"7","author":"Seitz","year":"2007","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.cld.2024.06.007_bib15","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fcell.2015.00040","article-title":"Dysfunctional mitochondrial bioenergetics and the pathogenesis of hepatic disorders","volume":"3","author":"Auger","year":"2015","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"10.1016\/j.cld.2024.06.007_bib16","first-page":"245","article-title":"Overview: how is alcohol metabolized by the body?","volume":"29","author":"Zakhari","year":"2006","journal-title":"Alcohol Res Health"},{"issue":"1","key":"10.1016\/j.cld.2024.06.007_bib17","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s00018-023-05061-7","article-title":"Contributing roles of mitochondrial dysfunction and hepatocyte apoptosis in liver diseases through oxidative stress, post-translational modifications, inflammation, and intestinal barrier dysfunction","volume":"81","author":"LeFort","year":"2024","journal-title":"Cell Mol Life Sci"},{"issue":"4","key":"10.1016\/j.cld.2024.06.007_bib18","first-page":"657","article-title":"CYP2E1--biochemical and toxicological aspects and role in alcohol-induced liver injury","volume":"73","author":"Cederbaum","year":"2006","journal-title":"Mt Sinai J Med"},{"issue":"3","key":"10.1016\/j.cld.2024.06.007_bib19","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1046\/j.1365-2710.2000.00282.x","article-title":"Cytochrome P450 2E1: its clinical and toxicological role","volume":"25","author":"Tanaka","year":"2000","journal-title":"J\u00a0Clin Pharm Ther"},{"issue":"12","key":"10.1016\/j.cld.2024.06.007_bib20","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1038\/s41417-022-00512-y","article-title":"CYP2E1-dependent upregulation of SIRT7 is response to alcohol mediated metastasis in hepatocellular carcinoma","volume":"29","author":"Zhang","year":"2022","journal-title":"Cancer Gene Ther"},{"issue":"9","key":"10.1016\/j.cld.2024.06.007_bib21","doi-asserted-by":"crossref","first-page":"2118","DOI":"10.1111\/j.1530-0277.1998.tb05925.x","article-title":"Early alcoholic liver injury: formation of protein adducts with acetaldehyde and lipid peroxidation products, and expression of CYP2E1 and CYP3A","volume":"22","author":"Niemela","year":"1998","journal-title":"Alcohol Clin Exp Res"},{"issue":"3","key":"10.1016\/j.cld.2024.06.007_bib22","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.cbi.2010.08.005","article-title":"Formation of acetaldehyde-derived DNA adducts due to alcohol exposure","volume":"188","author":"Yu","year":"2010","journal-title":"Chem Biol Interact"},{"issue":"11 Suppl","key":"10.1016\/j.cld.2024.06.007_bib23","first-page":"166S","article-title":"Activation of the innate immune system and alcoholic liver disease: effects of ethanol per se or enhanced intestinal translocation of bacterial toxins induced by ethanol?","volume":"29","author":"Bode","year":"2005","journal-title":"Alcohol Clin Exp Res"},{"issue":"1","key":"10.1016\/j.cld.2024.06.007_bib24","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0741-8329(02)00215-X","article-title":"Ethanol, oxidative stress, and cytokine-induced liver cell injury","volume":"27","author":"Hoek","year":"2002","journal-title":"Alcohol"},{"issue":"11 Suppl","key":"10.1016\/j.cld.2024.06.007_bib25","first-page":"110S","article-title":"Oxidative stress and signal transduction pathways in alcoholic liver disease","volume":"29","author":"Zima","year":"2005","journal-title":"Alcohol Clin Exp Res"},{"issue":"6","key":"10.1016\/j.cld.2024.06.007_bib26","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s00432-003-0439-5","article-title":"Genetic polymorphisms of tobacco- and alcohol-related metabolizing enzymes and the risk of hepatocellular carcinoma","volume":"129","author":"Munaka","year":"2003","journal-title":"J\u00a0Cancer Res Clin Oncol"},{"issue":"5","key":"10.1016\/j.cld.2024.06.007_bib27","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.ypmed.2003.11.027","article-title":"A\u00a0meta-analysis of alcohol consumption and the risk of 15 diseases","volume":"38","author":"Corrao","year":"2004","journal-title":"Prev Med"},{"issue":"2","key":"10.1016\/j.cld.2024.06.007_bib28","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jhep.2004.10.005","article-title":"Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma","volume":"42","author":"Marrero","year":"2005","journal-title":"J\u00a0Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2024.06.007_bib29","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1054\/bjoc.2001.2140","article-title":"A\u00a0meta-analysis of alcohol drinking and cancer risk","volume":"85","author":"Bagnardi","year":"2001","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.cld.2024.06.007_bib30","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1093\/aje\/155.4.323","article-title":"Alcohol and hepatocellular carcinoma: the effect of lifetime intake and hepatitis virus infections in men and women","volume":"155","author":"Donato","year":"2002","journal-title":"Am J Epidemiol"},{"issue":"5","key":"10.1016\/j.cld.2024.06.007_bib31","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0215(19990531)81:5<695::AID-IJC4>3.0.CO;2-W","article-title":"Case-control study on hepatitis C virus (HCV) as a risk factor for hepatocellular carcinoma: the role of HCV genotypes and the synergism with hepatitis B virus and alcohol. Brescia HCC Study","volume":"81","author":"Tagger","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.cld.2024.06.007_bib32","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1186\/1471-2407-11-446","article-title":"How the risk of liver cancer changes after alcohol cessation: a review and meta-analysis of the current literature","volume":"11","author":"Heckley","year":"2011","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.cld.2024.06.007_bib33","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1038\/ng.3417","article-title":"A\u00a0genome-wide association study confirms PNPLA3 and identifies TM6SF2 and MBOAT7 as risk loci for alcohol-related cirrhosis","volume":"47","author":"Buch","year":"2015","journal-title":"Nat Genet"},{"issue":"12","key":"10.1016\/j.cld.2024.06.007_bib34","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1038\/ng.257","article-title":"Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease","volume":"40","author":"Romeo","year":"2008","journal-title":"Nat Genet"},{"issue":"6","key":"10.1016\/j.cld.2024.06.007_bib35","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1038\/ajg.2015.137","article-title":"PNPLA3 gene polymorphism is associated with predisposition to and severity of alcoholic liver disease","volume":"110","author":"Salameh","year":"2015","journal-title":"Am J Gastroenterol"},{"issue":"5","key":"10.1016\/j.cld.2024.06.007_bib36","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/hep.31535","article-title":"Genome-wide association study and meta-analysis on alcohol-associated liver cirrhosis identifies genetic risk factors","volume":"73","author":"Schwantes-An","year":"2021","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2024.06.007_bib37","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000431","article-title":"A\u00a0polygenic risk score for alcohol-associated cirrhosis among heavy drinkers with European ancestry","volume":"8","author":"Schwantes-An","year":"2024","journal-title":"Hepatol Commun"},{"issue":"9055","key":"10.1016\/j.cld.2024.06.007_bib38","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.cld.2024.06.007_bib39","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cncr.20427","article-title":"Synergism of alcohol, diabetes, and viral hepatitis on the risk of hepatocellular carcinoma in blacks and whites in the U.S","volume":"101","author":"Yuan","year":"2004","journal-title":"Cancer"},{"issue":"10","key":"10.1016\/j.cld.2024.06.007_bib40","doi-asserted-by":"crossref","first-page":"705","DOI":"10.7326\/0003-4819-144-10-200605160-00004","article-title":"The prevalence of hepatitis C virus infection in the United States, 1999 through 2002","volume":"144","author":"Armstrong","year":"2006","journal-title":"Ann Intern Med"},{"issue":"3","key":"10.1016\/j.cld.2024.06.007_bib41","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1002\/hep.1840190303","article-title":"Clinical significance of concomitant hepatitis C infection in patients with alcoholic liver disease","volume":"19","author":"Fong","year":"1994","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2024.06.007_bib42","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1053\/jhep.2002.36780","article-title":"Risk factors for hepatocellular carcinoma: synergism of alcohol with viral hepatitis and diabetes mellitus","volume":"36","author":"Hassan","year":"2002","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2024.06.007_bib43","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/ajg.2010.477","article-title":"Hepatic and extrahepatic cancer in cirrhosis: a longitudinal cohort study","volume":"106","author":"Berman","year":"2011","journal-title":"Am J Gastroenterol"},{"issue":"4 Suppl","key":"10.1016\/j.cld.2024.06.007_bib44","first-page":"64S","article-title":"Clinical characteristics of patients in their 40s with HCV antibody-positive hepatocellular carcinoma","volume":"24","author":"Shimauchi","year":"2000","journal-title":"Alcohol Clin Exp Res"},{"issue":"3","key":"10.1016\/j.cld.2024.06.007_bib45","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1055\/s-2004-832942","article-title":"Alcohol and hepatitis C","volume":"24","author":"Safdar","year":"2004","journal-title":"Semin Liver Dis"},{"issue":"6","key":"10.1016\/j.cld.2024.06.007_bib46","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/S0168-8278(03)00414-8","article-title":"Alcohol and hepatitis C virus core protein additively increase lipid peroxidation and synergistically trigger hepatic cytokine expression in a transgenic mouse model","volume":"39","author":"Perlemuter","year":"2003","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.cld.2024.06.007_bib47","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1016\/S0039-6060(97)90313-5","article-title":"High malignancy of hepatocellular carcinoma in alcoholic patients with hepatitis C virus","volume":"121","author":"Kubo","year":"1997","journal-title":"Surgery"},{"issue":"8","key":"10.1016\/j.cld.2024.06.007_bib48","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1111\/j.1349-7006.1996.tb02113.x","article-title":"Effect of heavy alcohol intake on long-term results after curative resection of hepatitis C virus-related hepatocellular carcinoma","volume":"87","author":"Okada","year":"1996","journal-title":"Jpn J Cancer Res"},{"issue":"12","key":"10.1016\/j.cld.2024.06.007_bib49","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1111\/j.1440-1746.2011.06785.x","article-title":"Risk factors for hepatocellular carcinoma in a cohort infected with hepatitis B or C","volume":"26","author":"Walter","year":"2011","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2024.06.007_bib50","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1002\/hep.32542","article-title":"NAFLD-related hepatocellular carcinoma: the growing challenge","volume":"77","author":"Shah","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2024.06.007_bib51","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2022.08.030","article-title":"Alcohol consumption and metabolic syndrome: clinical and epidemiological impact on liver disease","volume":"78","author":"Aberg","year":"2023","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2024.06.007_bib52","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.cgh.2005.12.007","article-title":"The association between diabetes and hepatocellular carcinoma: a systematic review of epidemiologic evidence","volume":"4","author":"El-Serag","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2024.06.007_bib53","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.bjc.6603932","article-title":"Overweight, obesity and risk of liver cancer: a meta-analysis of cohort studies","volume":"97","author":"Larsson","year":"2007","journal-title":"Br J Cancer"},{"issue":"2","key":"10.1016\/j.cld.2024.06.007_bib54","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1002\/dmrr.1291","article-title":"Diabetes mellitus and risk of hepatocellular carcinoma: a systematic review and meta-analysis","volume":"28","author":"Wang","year":"2012","journal-title":"Diabetes Metab Res Rev"},{"issue":"2","key":"10.1016\/j.cld.2024.06.007_bib55","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1002\/hep.24397","article-title":"Metabolic syndrome increases the risk of primary liver cancer in the United States: a study in the SEER-Medicare database","volume":"54","author":"Welzel","year":"2011","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.cld.2024.06.007_bib56","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1002\/cncr.29971","article-title":"Population attributable fractions of risk factors for hepatocellular carcinoma in the United States","volume":"122","author":"Makarova-Rusher","year":"2016","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.cld.2024.06.007_bib57","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1002\/hep.31014","article-title":"Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease","volume":"71","author":"Kanwal","year":"2020","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2024.06.007_bib58","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/aje\/kws252","article-title":"Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study","volume":"177","author":"Loomba","year":"2013","journal-title":"Am J Epidemiol"},{"issue":"10","key":"10.1016\/j.cld.2024.06.007_bib59","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1016\/j.cgh.2010.06.027","article-title":"Obesity and alcohol synergize to increase the risk of incident hepatocellular carcinoma in men","volume":"8","author":"Loomba","year":"2010","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2024.06.007_bib60","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.jhep.2019.05.008","article-title":"Models estimating risk of hepatocellular carcinoma in patients with alcohol or NAFLD-related cirrhosis for risk stratification","volume":"71","author":"Ioannou","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.cld.2024.06.007_bib61","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/jgh.14770","article-title":"Genetic and lifestyle risk factors for advanced liver disease among men and women","volume":"35","author":"Sahlman","year":"2020","journal-title":"J\u00a0Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2024.06.007_bib62","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1007\/s10620-016-4085-6","article-title":"Day CP. Hepatocellular carcinoma in obesity, type 2 diabetes, and NAFLD","volume":"61","author":"Reeves","year":"2016","journal-title":"Dig Dis Sci"},{"issue":"6","key":"10.1016\/j.cld.2024.06.007_bib63","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","article-title":"AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma","volume":"78","author":"Singal","year":"2023","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2024.06.007_bib64","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","article-title":"Electronic address eee, European association for the study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma","volume":"69","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2024.06.007_bib65","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jhep.2018.07.022","article-title":"Estimate of hepatocellular carcinoma incidence in patients with alcoholic cirrhosis","volume":"69","author":"Ganne-Carrie","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2024.06.007_bib66","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cgh.2012.09.007","article-title":"Annual incidence of hepatocellular carcinoma among patients with alcoholic cirrhosis and identification of risk groups","volume":"11","author":"Mancebo","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.cld.2024.06.007_bib67","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.1002\/hep.24545","article-title":"Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities","volume":"54","author":"Trinchet","year":"2011","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2024.06.007_bib68","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/apt.13485","article-title":"Comparison between alcohol- and hepatitis C virus-related hepatocellular carcinoma: clinical presentation, treatment and outcome","volume":"43","author":"Bucci","year":"2016","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.cld.2024.06.007_bib69","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1111\/liv.15256","article-title":"Alcohol-related hepatocellular carcinoma is a heterogenous condition: lessons from a latent class analysis","volume":"42","author":"Costentin","year":"2022","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.cld.2024.06.007_bib70","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1136\/gutjnl-2019-319720","article-title":"Recent advances in alcohol-related liver disease (ALD): summary of a Gut round table meeting","volume":"69","author":"Avila","year":"2020","journal-title":"Gut"},{"issue":"9","key":"10.1016\/j.cld.2024.06.007_bib71","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1002\/cncr.31215","article-title":"Hepatocellular carcinoma is diagnosed at a later stage in alcoholic patients: results of a prospective, nationwide study","volume":"124","author":"Costentin","year":"2018","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.cld.2024.06.007_bib72","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10620-019-05724-1","article-title":"Geographical disparities of outcomes of hepatocellular carcinoma in France: the heavier burden of alcohol compared to hepatitis C","volume":"65","author":"Costentin","year":"2020","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.cld.2024.06.007_bib73","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.3390\/curroncol30030271","article-title":"Alcoholic liver disease-related hepatocellular carcinoma: characteristics and comparison to general Slovak hepatocellular cancer population","volume":"30","author":"Safcak","year":"2023","journal-title":"Curr Oncol"},{"key":"10.1016\/j.cld.2024.06.007_bib74","article-title":"Association of GLP-1 receptor agonists and hepatocellular carcinoma incidence and hepatic decompensation in patients with type 2 diabetes","author":"Wang","year":"2024","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2024.06.007_bib75","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.997578","article-title":"GLP-1 receptor agonist as a modulator of innate immunity","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.cld.2024.06.007_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106320","article-title":"The anti-inflammatory and immunological properties of GLP-1 Receptor Agonists","volume":"182","author":"Bendotti","year":"2022","journal-title":"Pharmacol Res"},{"issue":"12","key":"10.1016\/j.cld.2024.06.007_bib77","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.170671","article-title":"The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission","volume":"8","author":"Chuong","year":"2023","journal-title":"JCI Insight"},{"issue":"8","key":"10.1016\/j.cld.2024.06.007_bib78","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s11626-017-0181-y","article-title":"Inhibition of exendin-4-induced steatosis by protein kinase A in cultured HepG2 human hepatoma cells","volume":"53","author":"Chen-Liaw","year":"2017","journal-title":"In\u00a0Vitro Cell Dev Biol Anim"},{"key":"10.1016\/j.cld.2024.06.007_bib79","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejphar.2017.05.015","article-title":"Liraglutide, a glucagon-like peptide-1 analog, induce autophagy and senescence in HepG2 cells","volume":"809","author":"Krause","year":"2017","journal-title":"Eur J Pharmacol"},{"issue":"29","key":"10.1016\/j.cld.2024.06.007_bib80","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1038\/onc.2017.38","article-title":"The anti-diabetic drug exenatide, a glucagon-like peptide-1 receptor agonist, counteracts hepatocarcinogenesis through cAMP-PKA-EGFR-STAT3 axis","volume":"36","author":"Zhou","year":"2017","journal-title":"Oncogene"},{"issue":"1","key":"10.1016\/j.cld.2024.06.007_bib81","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/hep.21467","article-title":"Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets","volume":"45","author":"Boyault","year":"2007","journal-title":"Hepatology"},{"issue":"6","key":"10.1016\/j.cld.2024.06.007_bib82","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/hep.28123","article-title":"Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"issue":"8","key":"10.1016\/j.cld.2024.06.007_bib83","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100070","article-title":"Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma","volume":"1","author":"Abou-Alfa","year":"2022","journal-title":"NEJM Evid"},{"issue":"20","key":"10.1016\/j.cld.2024.06.007_bib84","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","article-title":"Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma","volume":"382","author":"Finn","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.cld.2024.06.007_bib85","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1038\/s41575-023-00754-7","article-title":"Nonalcoholic steatohepatitis-related hepatocellular carcinoma: pathogenesis and treatment","volume":"20","author":"Llovet","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2024.06.007_bib86","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ejca.2022.11.017","article-title":"Atezolizumab plus bevacizumab versus lenvatinib for unresectable hepatocellular carcinoma: a large real-life worldwide population","volume":"180","author":"Casadei-Gardini","year":"2023","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.cld.2024.06.007_bib87","doi-asserted-by":"crossref","first-page":"100591","DOI":"10.1016\/j.esmoop.2022.100591","article-title":"Atezolizumab plus bevacizumab versus lenvatinib or sorafenib in non-viral unresectable hepatocellular carcinoma: an international propensity score matching analysis","volume":"7","author":"Rimini","year":"2022","journal-title":"ESMO Open"},{"issue":"7854","key":"10.1016\/j.cld.2024.06.007_bib88","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1038\/s41586-021-03362-0","article-title":"NASH limits anti-tumour surveillance in immunotherapy-treated HCC","volume":"592","author":"Pfister","year":"2021","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.cld.2024.06.007_bib89","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jhep.2021.09.035","article-title":"Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score","volume":"76","author":"Scheiner","year":"2022","journal-title":"J\u00a0Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2024.06.007_bib90","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326124000552?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326124000552?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T16:48:38Z","timestamp":1732466918000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326124000552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":90,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1089326124000552"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2024.06.007","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alcohol and Hepatocellular Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2024.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}